Filsuvez (birch triterpenes) reduced the burden of wound dressing changes for people with dystrophic epidermolysis bullosa (DEB) and…
Articles by Lindsey Shapiro, PhD
In a small study in Japan, the topical gene therapy Vyjuvek (beremagene geperpavec) was shown to work similarly to…
The first recessive dystrophic epidermolysis bullosa (RDEB) patient will be dosed with the cell-based gene therapy Zevaskyn (prademagene…
PKC412, a medication already used for treating certain blood cancers, has the potential to be repurposed for treating epidermolysis…
The first person has been dosed in a Phase 3 trial testing KB803, Krystal Biotech’s experimental eye drop formulation…
Long-term treatment with the topical gene therapy Vyjuvek (beremagene geperpavec) was associated with continued wound closure and high patient…
Traws Pharma said it will advance development of skin cancer therapy rigosertib, after data showed the therapy led to a…
The European Commission has approved the topical gene therapy Vyjuvek (beremagene geperpavec) to treat wounds, starting at birth in…
Long-term treatment with Filsuvez (birch triterpenes) was well tolerated and associated with sustained reductions in wound burden for people…
In interviews, people with epidermolysis bullosa (EB) reported that living with these rare skin diseases has broad impacts on…
A gene-editing therapy made to correct a genetic defect in the LAMB3 gene that’s known to cause junctional epidermolysis…
Researchers have developed a framework for categorizing the severity of mutations in the COL7A1 gene that cause recessive dystrophic…